title: Emerging therapies for relapsing multiple sclerosis.
abstract: Six agents are currently approved by regulatory agencies to treat relapsing multiple sclerosis. Although these agents are effective and generally safe, some patients have continued disease activity or adverse effects. A sizable number of new agents are under investigation currently. This article reviews emerging agents that have shown promise in phase 2 trials.
authors: Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, Ohio 44195, USA. cohenj@ccf.org
authors: Jeffrey A
authors: JA
authors: Cohen
mesh_terms: D002986:Clinical Trials as Topic; D004638:Emergency Treatment / Q000379:methods*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D004964:Estriol / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy*
chemical_list: D004791:Enzyme Inhibitors; D007155:Immunologic Factors; D004964:Estriol